Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

被引：0
|
作者：
Aixin Shi
Panpan Xie
Lasse Lykke Nielsen
Trine Vang Skjøth
Xuemei He
Sine Pfeiffer Haugaard
机构：
[1] Chinese Academy of Medical Sciences,Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine
[2] Novo Nordisk A/S,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Diabetes; Glucagon-like peptide-1 receptor agonist; Pharmacokinetics; Randomised controlled trial; Semaglutide; Steady state exposure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：550 / 561
页数：11
相关论文
共 50 条
  • [31] Safety, tolerance, and pharmacokinetics of salvianolic acid B in healthy Chinese volunteers: A randomized, double-blind, placebo-controlled phase 1 clinical trial
    Cheng, Junlin
    Long, Jun
    Zhang, Jingjing
    Han, Le
    Hu, Yunfang
    Liu, Jianghui
    Qiu, Runze
    Zhu, Zhibin
    Fan, Hongwei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [32] Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Once-Weekly Human GLP-1 Analog, in Subjects With and Without Renal Impairment
    Marbury, Thomas C.
    Flint, Anne
    Segel, Stine
    Lindegaard, Marie
    Lasseter, Kenneth C.
    DIABETES, 2014, 63 : A260 - A260
  • [33] Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analogue, in subjects with and without renal impairment
    Marbury, T. C.
    Flint, A.
    Segel, S.
    Lindegaard, M.
    Lasseter, K. C.
    DIABETOLOGIA, 2014, 57 : S358 - S359
  • [34] Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
    Li, Yi
    Toyama, Kaoru
    Nakatsu, Takafumi
    Ishizuka, Hitoshi
    Wu, Hailan
    Cao, Guoying
    Yu, Jicheng
    Wang, Yu
    Liu, Xiaofen
    Guo, Beining
    Wu, Jufang
    Yu, Peimin
    Hong, Zhen
    Zhang, Jing
    Wu, Xiaojie
    ADVANCES IN THERAPY, 2023, 40 (04) : 1628 - 1643
  • [35] Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
    Yi Li
    Kaoru Toyama
    Takafumi Nakatsu
    Hitoshi Ishizuka
    Hailan Wu
    Guoying Cao
    Jicheng Yu
    Yu Wang
    Xiaofen Liu
    Beining Guo
    Jufang Wu
    Peimin Yu
    Zhen Hong
    Jing Zhang
    Xiaojie Wu
    Advances in Therapy, 2023, 40 (4) : 1628 - 1643
  • [36] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial
    Jing, Shan
    Xu, Ranchi
    Yang, Kexu
    Liu, Wenfang
    Zhang, Leduo
    Ke, Ying
    Xia, Guangxin
    Lin, Yang
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 735 - +
  • [37] Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects A Randomized, Double-Blind, Placebo-Controlled, Phase I Study
    Derks, Michael
    Anzures-Cabrera, Judith
    Turnbull, Lynn
    Phelan, Mary
    CLINICAL DRUG INVESTIGATION, 2011, 31 (05) : 325 - 335
  • [38] A phase 1, single-center, randomized, double-blind, placebo controlled, single ascending dose study to investigate the safety, tolerability, and pharmacokinetics of intravenous and subcutaneous garadacimab (CSL312) in healthy subjects
    McKenzie, A.
    Roberts, A.
    Malandkar, S.
    Feuersenger, H.
    Panousis, C.
    Pawaskar, D.
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 562 - 563
  • [39] Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
    McGowan, Barbara M.
    Bruun, Jens M.
    Capehorn, Matt
    Pedersen, Sue D.
    Pietilainen, Kirsi H.
    Muniraju, Hanna Angelene Kudiyanur
    Quiroga, Maria
    Varbo, Anette
    Lau, David C. W.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (09): : 631 - 642
  • [40] Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
    Wang, Wei
    Zhang, Shengnan
    Dou, Changlin
    Hu, Baihui
    Song, Hongtao
    Qi, Fan
    Zhao, Yanyan
    Li, Xiaojing
    Zhou, Ming
    Xie, Jinlian
    Deng, Kunhong
    Wu, Qian
    Ye, Ling
    Cui, Chang
    Liu, Li
    Huang, Jie
    Yang, Guoping
    BIODRUGS, 2024, 38 (06) : 855 - 865
12345